Protection of pancreatic islets from oxidative cell death by a peripherally-active morphinan with increased drug safety

[1]  R. Heidari,et al.  Dextromethorphan improves locomotor activity and decreases brain oxidative stress and inflammation in an animal model of acute liver failure , 2022, Clinical and experimental hepatology.

[2]  M. Roden,et al.  Mitochondrial respiration is decreased in visceral but not subcutaneous adipose tissue in obese individuals with fatty liver disease. , 2022, Journal of hepatology.

[3]  Vivek P. Chavda,et al.  Tirzepatide, a New Era of Dual-Targeted Treatment for Diabetes and Obesity: A Mini-Review , 2022, Molecules.

[4]  Yahiya Y. Syed.  Tirzepatide: First Approval , 2022, Drugs.

[5]  M. Rosenkilde,et al.  GLP-1 and GIP receptor signaling in beta cells – A review of receptor interactions and co-stimulation , 2022, Peptides.

[6]  Nai-Ching Chen,et al.  Dextromethorphan Reduces Oxidative Stress and Inhibits Uremic Artery Calcification , 2021, International Journal of Molecular Sciences.

[7]  Tsutomu Suzuki,et al.  Involvement of the Peripheral μ-Opioid Receptor in Tramadol-Induced Constipation in Rodents. , 2021, Biological & pharmaceutical bulletin.

[8]  E. Mayatepek,et al.  Peripherally active dextromethorphan derivatives lower blood glucose levels by targeting pancreatic islets. , 2021, Cell chemical biology.

[9]  D. Selvarajah,et al.  Pathogenesis, diagnosis and clinical management of diabetic sensorimotor peripheral neuropathy , 2021, Nature Reviews Endocrinology.

[10]  Yanfang Xu,et al.  Cardiac hERG K+ Channel as Safety and Pharmacological Target. , 2021, Handbook of experimental pharmacology.

[11]  N. Vaziri,et al.  The Role of Oxidative Stress in Pancreatic β Cell Dysfunction in Diabetes , 2021, International journal of molecular sciences.

[12]  C. Ämmälä,et al.  Human Islet Microtissues as an In Vitro and an In Vivo Model System for Diabetes , 2021, International journal of molecular sciences.

[13]  M. Canals,et al.  The Life Cycle of the Mu-Opioid Receptor. , 2020, Trends in biochemical sciences.

[14]  O. Schnell,et al.  Current concepts in the management of diabetic polyneuropathy , 2020, Journal of diabetes investigation.

[15]  K. Boye,et al.  Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study , 2020, Diabetes, obesity & metabolism.

[16]  S. Mignani,et al.  hERG toxicity assessment: Useful guidelines for drug design. , 2020, European journal of medicinal chemistry.

[17]  N. Volkow,et al.  The Changing Opioid Crisis: development, challenges and opportunities , 2020, Molecular Psychiatry.

[18]  A. Hierlemann,et al.  In Vitro Platform for Studying Human Insulin Release Dynamics of Single Pancreatic Islet Microtissues at High Resolution , 2020, Advanced biosystems.

[19]  M. Hall,et al.  The Opioid Crisis and the Future of Addiction and Pain Therapeutics , 2019, The Journal of Pharmacology and Experimental Therapeutics.

[20]  P. Newsholme,et al.  Oxidative stress pathways in pancreatic beta cells and insulin sensitive cells and tissues - importance to cell metabolism, function and dysfunction. , 2019, American journal of physiology. Cell physiology.

[21]  M. Gannon,et al.  The Beta Cell in Type 2 Diabetes , 2019, Current Diabetes Reports.

[22]  E. Feldman,et al.  Diabetic neuropathy , 2019, Nature Reviews Disease Primers.

[23]  A. Miki,et al.  Divergent antioxidant capacity of human islet cell subsets: A potential cause of beta-cell vulnerability in diabetes and islet transplantation , 2018, PloS one.

[24]  E. Mayatepek,et al.  NMDAR antagonists for the treatment of diabetes mellitus—Current status and future directions , 2017, Diabetes, obesity & metabolism.

[25]  T. Fischmann,et al.  Discovery of 3-morpholino-imidazole[1,5-a]pyrazine BTK inhibitors for rheumatoid arthritis. , 2017, Bioorganic & medicinal chemistry letters.

[26]  K. Khunti,et al.  Type 2 diabetes , 2017, The Lancet.

[27]  G. Rutter,et al.  The Role of Oxidative Stress and Hypoxia in Pancreatic Beta-Cell Dysfunction in Diabetes Mellitus. , 2017, Antioxidants & redox signaling.

[28]  M. Roden,et al.  Acute dietary fat intake initiates alterations in energy metabolism and insulin resistance , 2017, The Journal of clinical investigation.

[29]  E. Rouse,et al.  Recreational use of dextromethorphan, "Robotripping"-A brief review. , 2016, The American journal on addictions.

[30]  S. Traynelis,et al.  Pharmacology of dextromethorphan: Relevance to dextromethorphan/quinidine (Nuedexta®) clinical use. , 2016, Pharmacology & therapeutics.

[31]  A Thomas McLellan,et al.  Opioid Abuse in Chronic Pain--Misconceptions and Mitigation Strategies. , 2016, The New England journal of medicine.

[32]  E. Lammert,et al.  Exciting Times for Pancreatic Islets: Glutamate Signaling in Endocrine Cells , 2016, Trends in Endocrinology & Metabolism.

[33]  T. Heise,et al.  Effects of dextromethorphan as add‐on to sitagliptin on blood glucose and serum insulin concentrations in individuals with type 2 diabetes mellitus: a randomized, placebo‐controlled, double‐blinded, multiple crossover, single‐dose clinical trial , 2015, Diabetes, obesity & metabolism.

[34]  P. Dicpinigaitis.  Clinical perspective - cough: an unmet need. , 2015, Current opinion in pharmacology.

[35]  Rohit N. Kulkarni,et al.  Human β-Cell Proliferation and Intracellular Signaling: Part 3 , 2015, Diabetes.

[36]  Peter Kreiner,et al.  The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. , 2015, Annual review of public health.

[37]  T. Heise,et al.  Characterization of pancreatic NMDA receptors as possible drug targets for diabetes treatment , 2015, Nature Medicine.

[38]  P. Pagel,et al.  “Robo-Tripping”: Dextromethorphan Abuse and its Anesthetic Implications , 2014, Anesthesiology and pain medicine.

[39]  G. Shulman,et al.  Tissue-Specific Differences in the Development of Insulin Resistance in a Mouse Model for Type 1 Diabetes , 2014, Diabetes.

[40]  C. Ling,et al.  β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment , 2014, Diabetes Care.

[41]  B. Wagner,et al.  Targeting the pancreatic β-cell to treat diabetes , 2014, Nature Reviews Drug Discovery.

[42]  M. Raspa,et al.  FELASA recommendations for the health monitoring of mouse, rat, hamster, guinea pig and rabbit colonies in breeding and experimental units , 2014, Laboratory animals.

[43]  Gareth J Waldron,et al.  Reducing safety-related drug attrition: the use of in vitro pharmacological profiling , 2012, Nature Reviews Drug Discovery.

[44]  Tao-Cheng Wu,et al.  Low-Dose Dextromethorphan, a NADPH Oxidase Inhibitor, Reduces Blood Pressure and Enhances Vascular Protection in Experimental Hypertension , 2012, PloS one.

[45]  C. Talchai,et al.  Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure , 2012, Cell.

[46]  Johannes E. Schindelin,et al.  Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.

[47]  Eva L Feldman,et al.  Diabetic neuropathy: clinical manifestations and current treatments , 2012, The Lancet Neurology.

[48]  R. Thisted,et al.  Efficacy and safety of dextromethorphan/quinidine at two dosage levels for diabetic neuropathic pain: a double-blind, placebo-controlled, multicenter study. , 2012, Pain medicine.

[49]  Peter J. S. Smith,et al.  The level of menadione redox-cycling in pancreatic β-cells is proportional to the glucose concentration: role of NADH and consequences for insulin secretion. , 2012, Toxicology and applied pharmacology.

[50]  J. Ampuero,et al.  Sentinel Surveillance of Influenza-Like-Illness in Two Cities of the Tropical Country of Ecuador: 2006–2010 , 2011, PloS one.

[51]  J. Pankow,et al.  Glycated hemoglobin, diabetes, and cardiovascular risk in nondiabetic adults. , 2010, The New England journal of medicine.

[52]  W. R. Bishop,et al.  Discovery of C-imidazole azaheptapyridine FPT inhibitors. , 2010, Bioorganic & medicinal chemistry letters.

[53]  S. Bornstein,et al.  A new collagenase blend increases the number of islets isolated from mouse pancreas , 2009, Islets.

[54]  Hua-Lin Wu,et al.  Dextromethorphan reduces oxidative stress and inhibits atherosclerosis and neointima formation in mice. , 2009, Cardiovascular research.

[55]  W. Tsai,et al.  Treatment with dextromethorphan improves endothelial function, inflammation and oxidative stress in male heavy smokers , 2008, Journal of thrombosis and haemostasis : JTH.

[56]  Haruhiko Abe,et al.  Blockade of HERG cardiac K+ current by antifungal drug miconazole , 2005, British journal of pharmacology.

[57]  B. Liu,et al.  Protective effect of dextromethorphan against endotoxic shock in mice. , 2005, Biochemical pharmacology.

[58]  A J Camm,et al.  Arrhythmogenic mechanisms of non‐sedating antihistamines , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[59]  M. Max,et al.  High‐dose oral dextromethorphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia , 1997, Neurology.

[60]  R. Bergman,et al.  Modeling Error and Apparent Isotope Discrimination Confound Estimation of Endogenous Glucose Production During Euglycemic Glucose Clamps , 1988, Diabetes.

[61]  J. Daly,et al.  Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[62]  R. Steele,et al.  INFLUENCES OF GLUCOSE LOADING AND OF INJECTED INSULIN ON HEPATIC GLUCOSE OUTPUT * , 1959, Annals of the New York Academy of Sciences.

[63]  Qing Zhao,et al.  Staurosporine Induces Platelet Apoptosis Through p38 Mitogen-Activated Protein Kinase Signaling Pathway. , 2015, Clinical laboratory.